Clinical Trials Logo

Pulmonary Aspergillosis clinical trials

View clinical trials related to Pulmonary Aspergillosis.

Filter by:

NCT ID: NCT00585364 Completed - Cystic Fibrosis Clinical Trials

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

ABPA
Start date: March 2005
Phase: N/A
Study type: Observational

The goal of this study is to identify the immunological factors that influence a patient's response to the presence of the fungus Aspergillus fumigatus (A. fumigatus) in the lungs. In patients with cystic fibrosis (CF), this fungus is not known to cause damage to the lungs, but some patients respond with an allergic reaction that may cause wheeze, cough, or difficulty breathing. Approximately 230 patients will be enrolled with an additional 60 people who do not have CF and who do not have a history of asthma to serve as a comparison group.

NCT ID: NCT00501098 Completed - Clinical trials for Invasive Pulmonary Aspergillosis

Prophylaxis of Fungal Invasive Infections in Leukemia

PROFIL-C
Start date: January 2007
Phase: Phase 2
Study type: Interventional

- To assess the overall clinical yield - in terms of efficacy and safety endpoints of adding caspofungin as prophylaxis of Invasive Pulmonary Aspergillosis in patients undergoing induction treatment for newly diagnosed acute leukemia - To investigate the prognostic significance of Ptx3 at diagnosis and during the first chemotherapy cycle with respect to the development of IPA

NCT ID: NCT00391014 Completed - Clinical trials for Acute Myeloid Leukemia

Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis

AMBINEB
Start date: January 2006
Phase: Phase 2
Study type: Interventional

The trial is planned as a multicentric, national, phase II, open-label trial to evaluate safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during the induction therapy ,intensification, plus Allogeneic Haematopoietic Progenitor Cell transplant in due course, as well for patients diagnosed of several malignant haematologic diseases and treated with Allogeneic Haematopoietic Progenitor Cell Transplant

NCT ID: NCT00159822 Completed - Aspergillosis Clinical Trials

Voriconazole For Chronic Bronchopulmonary Aspergillosis

Start date: July 2005
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary